Literature DB >> 15740728

Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.

Charlotte U Andersen1, Michael J Mulvany, Ulf Simonsen.   

Abstract

The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats. Two weeks of hypoxia increased right ventricular systolic pressure, and right ventricular and lung weight. Treatment with either sildenafil (10 mg/kg/day) or molsidomine (15 mg/kg/day) in drinking water reduced right ventricular systolic pressure and weight, while lung weight was unchanged. Combining sildenafil and molsidomine did not have additional effects compared to molsidomine alone. The number of muscularized pulmonary arteries with diameters below 50 microm was increased in vehicle and sildenafil-treated, but not in molsidomine-treated hypoxic rats. Acetylcholine relaxation was blunted in arteries from vehicle and molsidomine-treated, but not in sildenafil-treated rats. In conclusion, both sildenafil and molsidomine blunts pulmonary hypertension and right ventricular hypertrophy in chronic hypoxic rats, but no synergistic effects were observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740728     DOI: 10.1016/j.ejphar.2005.01.020

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats.

Authors:  Morten Laursen; Lilliana Beck; Jan Kehler; Claus Tornby Christoffersen; Christoffer Bundgaard; Susie Mogensen; Tomas Joachim Mow; Estéfano Pinilla; Jakob Schöllhammer Knudsen; Elise Røge Hedegaard; Morten Grunnet; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

2.  Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle.

Authors:  Wenju Lu; Pixin Ran; Dandan Zhang; Gongyong Peng; Bing Li; Nanshan Zhong; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-04       Impact factor: 4.249

3.  CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation.

Authors:  Na Li; De-Zai Dai; Yin Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

4.  Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension.

Authors:  Melanie Reinero; Maurice Beghetti; Piergiorgio Tozzi; Ludwig K von Segesser; Michele Samaja; Giuseppina Milano
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-05-08       Impact factor: 2.457

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.